MOST NOTEWORTHY:

• Halozyme (NASDAQ: HALO) was initiated with a Buy rating and $14 target at Oppenheimer. The firm is positive on Halozyme's prospects for signing additional multi-product Enhanze deals in the next 12 months and the company's expanding internal pipeline.

• Oppenheimer also initiated shares of Rosetta Genomics (NASDAQ: ROSG) with a Buy rating and $11 target, as the firm is positive on Rosetta's intellectual property position in the emerging microRNA field related to the development and commercialization of research, diagnostic and therapeutic products, and other applications.

• Goldman Sachs resumed coverage of U.S. Steel Group (NYSE: X) with a Neutral rating.

• BioFuel Energy (NASDAQ: BIOF) was initiated with a Neutral rating at Cowen, as the firm sees a lack of catalysts until the company's plants under construction come on line in Q108...

• Brightpoint (NASDAQ: CELL) was initiated with an Outperform rating and $18 target at Credit Suisse.

• MasterCard (NYSE: MA) was initiated with a Market Perform rating at Wachovia on valuation.

• Citigroup initiated shares of Signature Bank (NASDAQ: SBNY) with a Buy rating and $39 target and shares of Discover Financial Services (NYSE: DFS) with a Sell rating and $24 target.

• Pacific Growth Equities started shares of Altair Nanotechnologies (NASDAQ: ALTI) with a Neutral rating.

Analyst initiations 7-24-07: CELL, DFS, MA and X originally appeared on BloggingStocks on Tue, 24 Jul 2007 11:11:00 EST. Please see our terms for use of feeds.